Table 2.
Activity of compounds 4, 8, 15, 16, and 17a against cytomegalovirus (HCMV), herpes simplex virus-1 (HSV-1) and herpes simplex virus-1 (HSV-2) in human embryonic lung (HEL) cell cultures.
| Comp. | Antiviral activity EC50 (μM)a |
Cytotoxicity (μM) |
||||
|---|---|---|---|---|---|---|
| HMCV |
HSV-1 |
HSV-2 |
MMCb | |||
| AD-169 | Davis | (KOS) | TK− KOS ACVr | (G) | ||
| 4a | nd | >100 | >100 | >100 | >100 | >100 |
| 4b | >4 | >4 | >100 | >100 | >100 | >100 |
| 4c | nd | >0.16 | >100 | >100 | >100 | 4 |
| 4d | nd | >4 | >20 | >20 | >20 | 20 |
| 8a | nd | >4 | >20 | >20 | >20 | 20 |
| 8b | nd | >4 | >4 | >4 | >4 | 20 |
| 8c | nd | >20 | >100 | >100 | >100 | 100 |
| 15 | >4 | >4 | >100 | >100 | >100 | 20 |
| 16a | >4 | >4 | >100 | >100 | >100 | >4 |
| 16b | >20 | >20 | >20 | >20 | >20 | 100 |
| 16c | >20 | >20 | >20 | >20 | >20 | 20 |
| 16d | 76 | 100 | >100 | >100 | >100 | >100 |
| 17a | >4 | >4 | >100 | >100 | >100 | 20 |
| Ganciclovir | 3.1 | 2.1 | 0.09 | 100 | 0.03 | >100 |
| Cidofovir | 0.38 | 0.51 | 0.4 | 1.2 | 0.7 | >250 |
| Acyclovir | 0.08 | 112 | 0.2 | >250 | ||
| Brivudin | 0.007 | 50 | 96 | >250 | ||
a
Effective concentration required to reduce virus plaque formation by 50%. Virus input was 20 plaque-forming units (PFU).
b
Maximum cytotoxic concentration that cause a microscopically detectable alteration of morphology.